Search

Displaying results 1821 - 1830 of 7604 in total
  1. Drug

    Ferric derisomaltose

    go.drugbank.com/drugs/DB15617
    ApprovedInvestigational

    The latter is an iron carbohydrate oligosaccharide that works to release iron. Ferric derisomaltose was developed by Pharmacosmos Therapeutics ad was granted FDA approval in January 2020. … [L11581,L11587] Clinical trials show that it is non-inferior to [iron sucrose], another form of iron that is often administered in iron deficiency, and less likely to cause serious hypersensitivity that

  2. Drug

    Estradiol cypionate

    go.drugbank.com/drugs/DB13954
    ApprovedVet approved

    However, after menopause, most endogenous estrogen is produced by conversion of androstenedione, secreted by the adrenal cortex, to estrone by peripheral tissues. … First-pass metabolism by the gut and the liver quickly degrades the estradiol molecule before it gets a chance to enter systemic circulation and exert its estrogenic effects [A12102].

  3. Drug

    Eravacycline

    go.drugbank.com/drugs/DB12329
    ApprovedInvestigational

    It was first approved by the FDA on August 27, 2018 [L4540]. … Eravacycline, known as _Xerava_ by Tetraphase Pharmaceuticals, is a fully synthetic fluorocycline antibiotic of the tetracycline class with activity against clinically significant gram-negative, gram-positive

  4. Drug

    Tideglusib

    go.drugbank.com/drugs/DB12129
    ApprovedInvestigationalWithdrawn

    [A31601] Tideglusib is being developed by the Spanish pharmaceutic company Zeltia group and its current status is withdrawn for the treatment of Alzheimer's disease as of 2012. … It is reported to be a potent anti-inflammatory and neuroprotective that is a non-ATP competitive inhibitor of glycogen synthase kinase 3 (GSK-3).

  5. Drug

    Ziprasidone

    go.drugbank.com/drugs/DB00246
    ApprovedInvestigational

    generally thought to be as efficacious as first generation antipsychotics but differ in their adverse effect profiles. … [A190525] These mental illnesses can often be accompanied by comorbidities such as depression and substance abuse, and can significantly impact the quality of life of patients and caregivers.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  6. Drug

    Vedolizumab

    go.drugbank.com/drugs/DB09033
    ApprovedInvestigational

    to its more favorable safety profile compared to its predecessor natalizumab, the first integrin receptor antagonist approved by the FDA. … [L48216] Vedolizumab was developed by Takeda and approved by the FDA under the brand name ENTYVIO for the maintenance therapy of moderately to severely active Ulcerative Colitis and Crohn’s Disease

  7. Drug

    Talimogene laherparepvec

    go.drugbank.com/drugs/DB13896
    ApprovedInvestigational

    It was approved by the FDA in 2015 under the market name Imlygic. In general, talimogene laherparepvec has been modified so that it can infect and multiply inside melanoma cells [L2221]. … Alternatively, although talimogene laherparepvec also enters healthy cells, it is not designed to multiply inside them [L2221].

  8. Drug

    Odevixibat

    go.drugbank.com/drugs/DB16261
    ApprovedInvestigational

    [A236808,L34793] Odevixibat is the first approved non-surgical treatment option for PFIC.[L34803] Previous therapies for PFIC included a bile acid sequestrant such as [ursodeoxycholic acid]. … [A236808] Odevixibat was granted FDA and Health Canada approval on 20 July 2021 and 13 November 2023 respectively.[L34793,L49535]

  9. Drug

    Betrixaban

    go.drugbank.com/drugs/DB12364
    Approved

    Betrixaban is a non-vitamin K oral anticoagulant whose action is driven by the competitive and reversible inhibition of the factor Xa [A7708]. … Betrixaban, now developed by Portola Pharmaceuticals Inc., is prescribed as a venous thromboembolism (VTE) prophylactic for adult patients with moderate to severe restricted motility or with other risks

    Synonyms: N-(5-chloropyridin-2-yl)-2-(4-(N,N-dimethylcarbamimidoyl)benzamido)-5-methoxybenzamide, N-(5-chloropyridin-2-yl)-2-[[4-(N,N-dimethylcarbamimidoyl)benzoyl]amino]-5-methoxybenzamide
  10. Drug

    Chromium

    go.drugbank.com/drugs/DB11136
    ApprovedInvestigational

    According to the National Institute of Health, the daily dietary reference intake (DRI) of chromium for adult male and non-pregnant female are 35 μg and 25 μg, respectively [L1986]. … in commercial settings and are known to be human carcinogens [L1982].

    Mixtures: ADDAMEL N, Protect Plus SO 60